Skip to main content
ยาสำเร็จรูป

เมเพรซซอล

MEPRESSAL

Active

Found — certificate is active

FDA 1A15048/65

Matched in official databases: FDA · Last updated 2026-07-29

TaeJing aggregates official records — this is not a government endorsement · verify at the source via the table below (free)

เลขตรงแล้ว — เทียบกับของในมือด้วย

ของปลอมมักใช้วิธี "สวมเลข" คือเอาเลขของสินค้าอื่นที่มีจริงมาพิมพ์ เลข 1A15048/65 ต้องเป็นของ:

ชื่อบนฉลากต้องเป็น
เมเพรซซอล
ผู้ผลิต/ผู้นำเข้าบนฉลากต้องเป็น
บริษัท เอเบิ้ล เมดิคอล จำกัด

ถ้าชื่อหรือผู้ผลิตบนฉลากไม่ตรงกับที่นี่ อย่าเพิ่งซื้อ และแจ้งสายด่วน อย. 1556

Share this result:LINE

Product & certifications 1

  • FDA 1A15048/65ยาสำเร็จรูปคงอยู่
    Product type
    ยาสำเร็จรูป
    Permission
    ผย1
    Address
    บ้านเลขที่ 111 หมู่ 9 ตำบล หนองซอน อำเภอ เชียงยืน จังหวัด มหาสารคาม 44160โทร. -
    Foreign manufacturer
    บริษัท เอเบิ้ล เมดิคอล จำกัด
    Status at source
    คงอยู่
    Verify at the official source ↗

ตัวยาสำคัญ

  • .METHYLPREDNISOLONE SODIUM SUCCINATE1.367 gram
  • .METHYLPREDNISOLONE SODIUM SUCCINATE2.734 gram
  • .METHYLPREDNISOLONE SODIUM SUCCINATE341.37 milligram
  • .METHYLPREDNISOLONE SODIUM SUCCINATE683.50 milligram
  • METHYLPREDNISOLONE SODIUM SUCCINATE170.68 milligramต่อ 1 vial
ประเภทควบคุม
ยาควบคุมพิเศษ
ข้อบ่งใช้
-Endocrine disorders: • primary or secondary adrenocortical insufficiency (in conjunction with mineralocorticoids, where applicable); • acute adrenocortical insufficiency (mineralocorticoid supplementation may be necessary); • shock secondary to adrenocortical insufficiency, or shock unresponsive to conventional therapy when adrenocortical insufficiency may be present (when mineralocorticoid activity is undesirable); • preoperatively or in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful; • congenital adrenal hyperplasia; • non-suppurative thyroiditis; • hypercalcemia associated with cancer. -Rheumatic disorders (as adjunctive therapy for short-term administration in the management of an acute episode or exacerbation): • posttraumatic osteoarthritis; • synovitis of osteoarthritis; • rheumatoid arthritis, including juvenile rheumatoid arthritis; • acute and subacute bursitis; • epicondylitis; • acute nonspecific tenosynovitis; • acute gouty arthritis; • psoriatic arthritis; • ankylosing spondylitis. -Collagen diseases and immune complex diseases (during an exacerbation or as maintenance therapy in selected cases: • systemic lupus erythematosus; • acute rheumatic carditis; • systemic dermatomyositis (polymyositis). -Dermatologic disease: • pemphigus; • severe erythema multiforme (Stevens-Johnson syndrome); • exfoliative dermatitis; • severe psoriasis; • bullous dermatitis herpetiformis; • severe seborrheic dermatitis; • mycosis fungoides. -Allergic states (to control severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment): • bronchial asthma; • contact dermatitis; • atopic dermatitis; • serum sickness; • seasonal or perennial allergic rhinitis; • drug hypersensitivity reactions; • urticarial transfusion reaction; • acute noninfectious laryngeal edema. -Ophthalmic diseases (severe acute and chronic allergic and inflammatory processes involving the eye): • herpes-zoster ophthalmicus; • iritis, iridocyclitis; • chorioretinitis; • diffuse posterior uveitis and choroiditis; • optic neuritis; • sympathetic ophthalmia; • anterior segment inflammation; • allergic conjunctivitis; • allergic corneal marginal ulcers; • keratitis. -Gastrointestinal diseases (to manage critical period of the disease): • ulcerative colitis; • regional enteritis. -Respiratory disease: • symptomatic sarcoidosis; • berylliosis; • fulminating or disseminated tuberculosis (when used concurrently with appropriate antituberculous chemotherapy); • Loeffler’s syndrome not manageable by other means; • aspiration pneumonitis; • moderate to severe Pneumocystis jiroveci pneumonia in AIDS patients (as adjunctive therapy when given within the first 72 hours of initial anti-pneumocystis treatment). -Hematologic disorders: • acquired (autoimmune) hemolytic anemia; • idiopathic thrombocytopenic purpura in adult; • secondary thrombocytopenia in adults; • erythroblastopenia (RBC anemia); • congenital (erythroid) hypoplastic anemia. -Neoplastic diseases (palliative management): • leukemias and lymphomas in adults; • acute leukemia of childhood. -Edematous states: • To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia. -Nervous System: • acute exacerbations of multiple sclerosis. -Other indications: • tuberculous meningitis with subarachnoid block or impending block (when used concurrently with appropriate chemotherapy); • trichinosis with neurologic or myocardial involvement.
รหัส ATC
H02AB04 (methylprednisolone sodium succinate) · H02AB04 (methylprednisolone sodium succinate) · H02AB04 (methylprednisolone sodium succinate) · H02AB04 (methylprednisolone sodium succinate) · H02AB04 (methylprednisolone sodium succinate)

ข้อมูลตามที่ขึ้นทะเบียนกับ อย. — ไม่ใช่คำแนะนำการใช้ยา ปรึกษาเภสัชกรหรือแพทย์ก่อนใช้เสมอ

Trade name
—
Company / Manufacturer
บริษัท เอเบิ้ล เมดิคอล จำกัดดำเนินกิจการ
Juristic registration number
0105555008979

A matching registration number confirms the registration exists — it does not verify that the physical item you hold is genuine. Always compare the product and manufacturer names on the label.

Read guide: Certifications / Registrations →

Last updated: 2026-07-29 · Data aggregated from official government databases: NBTC · FDA · TISI · DBD · Dept. of Tourism · ACFSNot refreshed for 115 days — re-check at the sourceReport incorrect data

Found incorrect data? Report it here

We always verify with the official source before changing anything.